Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Related Party Disclosures (Tables)

v3.25.4
Related Party Disclosures (Tables)
12 Months Ended
Dec. 31, 2025
Disclosure of transactions between related parties [abstract]  
Summary of Transactions with Related Parties

The amounts of transactions with related parties recognized in the consolidated income statement and the related assets and liabilities are as follows:

For the year ended and at December 31, 2025

 

 

 

Revenue

 

 

Other income

 

 

Costs*

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

Parent company

 

 

 

 

 

 

 

 

 

Stevanato Holding S.r.l.

 

 

 

 

 

96

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

Società Agricola Stella S.r.l.

 

 

 

 

 

 

 

 

158

 

SFEM Italia S.r.l.

 

 

 

 

 

 

 

 

21

 

Studio Legale Spinazzi Azzarita Troi

 

 

 

 

 

 

 

 

118

 

Fondazione Stevanato

 

 

 

 

 

 

 

 

290

 

Incog BioPharma Services Inc

 

 

7,582

 

 

 

 

 

 

 

SIT S.p.A.

 

 

34

 

 

 

 

 

 

1

 

 

* Costs include cost of sales, selling, general administrative costs and other expenses net

 

 

 

Trade
receivables

 

 

Trade
payables

 

 

Other Assets

 

 

Contract Assets

 

 

Other
Liabilities

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parent company

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stevanato Holding S.r.l.

 

 

 

 

 

 

 

 

7,076

 

 

 

 

 

 

14,710

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Società Agricola Stella S.r.l.

 

 

 

 

 

59

 

 

 

 

 

 

 

 

 

 

Studio Legale Spinazzi Azzarita Troi

 

 

 

 

 

119

 

 

 

37

 

 

 

 

 

 

 

SIT Manufacturing

 

 

17

 

 

 

 

 

 

 

 

 

 

 

 

 

Incog BioPharma Services Inc

 

 

2,586

 

 

 

 

 

 

 

 

 

4,944

 

 

 

 

 

 

For the year ended and at December 31, 2024

 

 

 

Revenue

 

 

Other income

 

 

Costs*

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

Parent company

 

 

 

 

 

 

 

 

 

Stevanato Holding S.r.l.

 

 

 

 

 

266

 

 

 

7

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

Società Agricola Stella S.r.l.

 

 

 

 

 

1

 

 

 

165

 

SFEM Italia S.r.l.

 

 

 

 

 

 

 

 

21

 

E & FKH Ejendomme ApS

 

 

 

 

 

 

 

 

222

 

Studio Legale Spinazzi Azzarita Troi

 

 

 

 

 

 

 

 

198

 

Fondazione Stevanato

 

 

 

 

 

 

 

 

180

 

Incog BioPharma Services Inc

 

 

5,557

 

 

 

 

 

 

 

* Costs include cost of sales, selling, general administrative costs and other expenses net

 

 

 

 

Trade
receivables

 

 

Trade
payables

 

 

Other Assets

 

 

Contract Assets

 

 

Other
Liabilities

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parent company

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stevanato Holding S.r.l.

 

 

 

 

 

 

 

 

9,216

 

 

 

 

 

 

22,785

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Società Agricola Stella S.r.l.

 

 

 

 

 

113

 

 

 

 

 

 

 

 

 

 

SFEM Italia S.r.l.

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

Studio Legale Spinazzi Azzarita Troi

 

 

 

 

 

29

 

 

 

 

 

 

 

 

 

 

Incog BioPharma Services Inc

 

 

208

 

 

 

 

 

 

 

 

 

3,628

 

 

 

3

 

 

 

 

For the year ended December 31, 2023

 

 

 

Revenue

 

 

Costs*

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

Winckler & Co. Ltd.

 

 

 

 

 

191

 

Società Agricola Stella S.r.l.

 

 

 

 

 

110

 

SFEM Italia S.r.l.

 

 

 

 

 

20

 

E & FKH Ejendomme ApS

 

 

 

 

 

435

 

Studio Legale Spinazzi Azzarita Troi

 

 

 

 

 

311

 

Fondazione Stevanato

 

 

 

 

 

240

 

C.T.S. Studio AS

 

 

 

 

 

21

 

Incog BioPharma Services Inc

 

 

545

 

 

 

 

 

* Costs include cost of sales, selling, general administrative costs and other expenses net

 

Loan from/to related parties

For the year ended December 31, 2023

 

 

 

Interest
received

 

 

Interest
paid

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

SE Holdings Co.Ltd.

 

 

 

 

 

3

 

Summary of Emoluments to Directors and Key Management

Emoluments to Directors and Key Management

The tables below present the aggregate compensation of the members of the Board of Directors and the Senior Management Team. For the year ended December 31, 2025, the compensation of the Chairman and Chief Executive Officer, Franco Stevanato, is reported within Directors’ fees. For the years ended December 31, 2024 and 2023, the compensation of the Chairman, Franco Stevanato, was reported within emoluments to Directors, while the compensation of the Chief Executive Officer, Franco Moro, was reported within compensation to members of the Senior Management Team.

The fees of the Directors of Stevanato Group S.p.A. are as follows:

For the year ended December 31, 2025

 

 

Fixed remuneration

 

 

Variable

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

remuneration(2)

 

 

compensation (3)

 

 

remuneration

 

 

fee

 

 

benefits (1)

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Directors

 

 

2,078

 

 

 

9

 

 

 

290

 

 

 

996

 

 

 

3,373

 

 

 

(1) Fringe benefits related to car and insurance benefits

(2) Variable remuneration related to MBO for the Chairman and CEO

 

(3) Shares granted to board members

 

For the year ended December 31, 2024

 

 

Fixed remuneration

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

compensation (2)

 

 

remuneration

 

 

fee

 

 

benefits (1)

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Directors

 

 

1,970

 

 

 

6

 

 

 

459

 

 

 

2,435

 

 

(1) Fringe benefits related to car and insurance benefits

 

(2) Shares granted to board members

For the year ended December 31, 2023

 

 

Fixed remuneration

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

expense(2)

 

 

compensation (3)

 

 

remuneration

 

 

fee

 

 

benefits (1)

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Directors

 

 

2,242

 

 

 

12

 

 

 

70

 

 

 

438

 

 

 

2,762

 

 

(1) Fringe benefits related to car and insurance benefits

 

(2) Pensions expense related to "Trattamento Fine Mandato" accrued during the year

(3) Shares granted to board members

The aggregate compensation for members of the Senior Management Team is as follows:

For the year ended December 31, 2025

 

 

 

Fixed remuneration

 

 

Variable

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

remuneration(2)

 

 

expense (3)

 

 

compensation(4)

 

 

remuneration

 

 

fee

 

 

benefits(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Key Management

 

 

1,124

 

 

 

14

 

 

 

270

 

 

 

552

 

 

 

4

 

 

 

1,964

 

 

(1) Fringe benefits related to car and insurance benefits

(2) Variable remuneration related to MBO

(3) Pensions expense related to "Trattamento Fine Rapporto" accrued during the year and to certain severance payments

(4)Share‑based compensation includes amounts recognised under the stock grant plan 2023–2027 and other share‑based incentive plans, adjusted to reflect the Group’s best estimate of the number of equity instruments expected to vest.

 

For the year ended December 31, 2024

 

 

 

Fixed remuneration

 

 

Variable

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

remuneration(2)

 

 

expense(3)

 

 

compensation(4)

 

 

remuneration

 

 

fee

 

 

benefits(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Key Management

 

 

1,741

 

 

 

22

 

 

 

79

 

 

 

2,325

 

 

 

719

 

 

 

4,886

 

 

(1) Fringe benefits related to car and insurance benefits

(2) Variable remuneration related to MBO

(3) Pensions expense related to "Trattamento Fine Rapporto" accrued during the year and to certain severance payments

(4) Shares granted under stock grant plan 2023-2027 and other share-based incentive plans

For the year ended December 31, 2023

 

 

 

Fixed remuneration

 

 

Variable

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

remuneration(2)

 

 

expense(3)

 

 

compensation(4)

 

 

remuneration

 

 

fee

 

 

benefits(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Key Management

 

 

1,777

 

 

 

28

 

 

 

94

 

 

 

94

 

 

 

845

 

 

 

2,838

 

 

(1) Fringe benefits related to car and insurance benefits

(2) Variable remuneration related to MBO

(3) Pensions expense related to "Trattamento Fine Rapporto" accrued during the year

(4) Shares granted under stock grant plan 2023-2027 and other share-based incentive plans